What does political change in Washington actually mean for the life science sector? Speaking at BioStock Life Science Summit 2026 the morning after the US midterm elections, Andreas Dirnagl cut through the post-election noise with a sober assessment of what election outcomes tend to mean in practice.
His central message was that political control does not automatically translate into influence. With slim majorities, pushback from the courts and the checks built into the system, headline political victories rarely lead to immediate or sweeping policy changes, according to Dirnagl.
The discussion also turned to most-favoured-nation (MFN) pricing, the policy of linking US drug prices to the lowest prices paid in other developed countries. In response to a question from the audience, Dirnagl concluded that the US does not control global pharmaceutical pricing, and that the fine print in the pricing agreements struck with large pharmaceutical companies commits them to very little in practice.
Dirnagl is Head of Healthcare Strategy and Senior Client Advisor at DNB Bank in New York, with more than 30 years of experience in healthcare banking, equity research and advisory. Before joining DNB, he spent around a decade at MUFG as Global Head of Healthcare Research and Strategy, growing the healthcare business from 40 clients and USD 60 million a year to more than 140 clients and USD 270 million. He has also held senior healthcare roles at Deutsche Bank and J.P. Morgan.
See the full keynote address “Trump 2.0 – The Verdict: From uncertainty to Economic Reality” below.
